Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 77 clinical trials
SBRT With DIBH for HCC After TACE and Lipiodol Marking

, transcatheter arterial chemoembolization (TACE) and lipiodol marking, to analyze the recognition and clarity of lipiodol on CBCT images, set-up errors and treatment efficacy. Therefore to provide data to

TACE
metastasis
  • 0 views
  • 02 Sep, 2021
  • 1 location
TACE vs TACE+SBRT for Unresectable Hepatocellular Cancer (TACE-SBRT)

transarterial chemoembolization (TACE) or systemic chemotherapy (sorafenib) as standard of care. However, TACE alone is not a curative approach. The two year survival following TACE ranges from 31-63% with

stereotactic body radiation therapy
TACE
chemoembolization
sorafenib
systemic chemotherapy
  • 42 views
  • 11 May, 2022
  • 2 locations
TACE-HAIC vs. HAIC for Potentially Resectable HCC

to large tumors, surgical treatment is suitable for early-stage and well-reserved liver function patients. Therefore, in clinical practice, transarterial chemoembolization (TACE) is a preferential

liver transplant
antineoplastic
hepatic arterial infusion
TACE
chemoembolization
  • 3 views
  • 05 Mar, 2022
  • 1 location
TACE Combined With Lenvatinib Versus TACE Sequential Lenvatinib in the Treatment of Intermediate/Advanced Liver Cancer

TACE(transcatheter arterial chemoembolization) has been recommended by domestic and international guidelines as the standard treatment for a subset of HCC patients with very high heterogeneity

neutrophil count
cancer
TACE
platelet count
  • 0 views
  • 03 Jun, 2022
  • 1 location
Adjuvant Therapies for Patients With HCC and MVI (A-TACE/S-HCC)

, adjuvant transarterial chemoembolization (TACE) is reported to be effective in reducing early recurrence rate and mortality for patients with HCC with risk factors of recurrence. Sorafenib is a novel drug

Accepts healthy volunteers
TACE
metastasis
chemoembolization
sorafenib
  • 5 views
  • 24 Feb, 2022
  • 1 location
Feasibility of High Dose PROton Therapy On Unresectable Primary Carcinoma Of Liver: Prospective Phase II Trial

The standard treatment of unresectable hepatocellular carcinoma (HCC) is transarterial chemoembolization (TACE) or sorafenib. Though the TACE and the agent showed survival benefit in several

liver disease
carcinoma
neutrophil count
sorafenib
unresectable hepatocellular carcinoma
  • 18 views
  • 22 Jan, 2021
  • 1 location
High Dose-Rate Brachytherapy for the Treatment of Both Primary and Secondary Unresectable Liver Malignancies

ablative techniques and can also be utilized to treat lesions that are not amenable to intra-arterial therapies (such as trans-arterial chemoembolization and yttrium-90 radioembolization). Since

carcinoma
cancer
metastasis
  • 0 views
  • 12 May, 2022
  • 1 location
Assessment of the Efficacy of Lenvatinib Versus Sorafenib in the Management of Advanced Hepatocellular Carcinoma

limited treatment options for HCC patients who are ineligible for surgical resection. Locoregional therapies, such as radiofrequency ablation, transarterial chemoembolization (TACE), transarterial

erlotinib
tyrosine
TACE
cancer
  • 0 views
  • 02 Jun, 2022
  • 1 location
Tislelizumab in Combination With TACE in Advanced Hepatocellular Carcinoma

A multicentric, open-label, single-arm prospective study to assess the efficacy and safety of tislelizumab combined with TACE as first-line treatment in patients with unresectable BCLC stage C HCC.

  • 0 views
  • 27 Jan, 2021
  • 1 location
TACE Combined With Camrelizumab and Apatinib Versus TACE in Intermediate and Advanced Hepatocelluar Carcinoma: a Randomized, Open-label, Multi-center Clinical Trials

The purpose of this study is to evaluate the efficacy and safety of TACE in combination with Camrelizumab and Apatinib versus TACE in patients with intermediate- and advanced HCC.

cancer
TACE
  • 0 views
  • 20 Sep, 2022
  • 1 location